Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
AutoZone Vendor Summit Recognizes Contributions of Top Suppliers
-
Lifeist Sells Australian Vapes
-
West Red Lake Gold Outlines 2024 Madsen Mine Plans
-
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associate
-
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
-
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
-
GXO Releases 2023 ESG Impact Report
-
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
-
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
-
Instreamatic Announces New Opportunities for Brands to Access Professional Union Talent for Highly Personalized Ads
-
Statement from Bart Demosky, Executive Vice President and CFO, Bombardier, on S&P’s Global Ratings Upgrade from B to B+
-
Lantronix IoT Solution Enables Digital Retail Shelf Signage Solution for HY-LINE Group
-
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
-
Statement from Bart Demosky, Executive Vice President and CFO, Bombardier, on S&P’s Global Ratings Upgrade from B to B+
-
SPOD Lithium Amends Property Option Agreements and Appoints a New Director
-
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
-
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
-
Amplify ETFs Earns Four Nominations for With Intelligence Mutual Fund and ETF Awards
-
Mesa Regains Compliance with NASDAQ Minimum Bid Price Requirement
-
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
-
PyroGenesis Clears Final Requirement to Becoming Approved Titanium Powder Supplier to Global Aerospace OEM Client
-
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
-
Cibus to Participate in Upcoming June Investor Events
-
StepStone Closes Largest-Ever Venture Capital Secondaries Fund
-
GXO Releases 2023 ESG Impact Report
-
23andMe Launches New Genetic Report on Bipolar Disorder
-
ECARX Strengthens Strategic Partnership with Tencent to Jointly Develop Intelligent Vehicle Solutions
-
Currency Exchange International to Report its Second Quarter 2024 Results on June 12, 2024, and Host Earnings Conference Call on June 13, 2024 at 8:30 AM EST
-
YieldMax™ ETFs Announces Monthly Distributions on MSTY (106.33%), NVDY (101.82%), CONY (84.85%), YBIT (81.00%), AIYY (78.90%) and Others
-
Endeavour Announces Total Voting Rights
-
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
-
Lands’ End Announces First Quarter 2024 Results
-
Director Appointment
-
Albion Technology & General VCT PLC: Interim Management Statement
-
Sophos Uncovers Chinese Espionage Campaign in Southeast Asia
-
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
-
Colorado Ford Dealers Secure Naming Rights to New Outdoor Amphitheater in Colorado Springs, Colorado
-
THOR Industries Announces Third Quarter Fiscal 2024 Results
-
CNH and its brands support World Environment Day
-
Tims China Announces First Quarter 2024 Financial Results
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Wood Group (John) plc
-
Net Asset Value(s)
-
Fusion Fuel Green Hosts First Quarter 2024 Investor Update
-
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results
-
Calibre Continues to Discover Additional Gold Mineralization At the Valentine Gold Mine Demonstrating Upside Potential
-
Melcor Developments Ltd. Announces Normal Course Issuer Bid
-
PathMaker Neurosystems Announces $2.16 Million Award from U.S. Department of Defense for ALS Clinical Trial
-
Immutep successfully completes institutional placement and institutional component of entitlement offer
-
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
